Airbrush LipoSculpture(R) II System
Airbrush LipoSculpture(R) II System

Airbrush LipoSculpture(R) II System

press to zoom
Airbrush(R) LipoSculptor IIE
Airbrush(R) LipoSculptor IIE

Airbrush(R) LipoSculptor IIE

press to zoom
Six Pack Sampler
Six Pack Sampler

Six Pack Sampler

press to zoom
Airbrush LipoSculpture(R) II System
Airbrush LipoSculpture(R) II System

Airbrush LipoSculpture(R) II System

press to zoom
1/5
Corporate Capsule

     BioSculpture Technology, Inc. has patented and prototyped a minimally invasive EVL® device and method for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 Diabetes mellitus. Scientific research has confirmed that excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, decreasing the quality of human life and shortening the lives of those we love.

     We believe our patented technology and surgical procedure, Endoscopic Visceral Lipectomy (“EVL”), illustrated in this short medical video, will save and improve millions of human lives each year, while significantly reducing healthcare costs. While safety and efficacy studies are yet to be performed and regulatory approvals obtained, the Company believes an EVL procedure may not only replace Lap-band® but will do for obesity treatment what LASER eye surgery has done for vision correction.

Medical Advance

     The medical movie provides a brief description and depiction of a proposed Endoscopic Visceral Lipectomy or an " EVL" procedure carried out with BioSculpture Technology, Inc.'s patented method and EVL(R) device to remove the visceral or "belly" fat which causes $2 Trillion dollars of yearly obesity-related diseases including, gastric reflux, sleep apnea, hypertension, cancers and autoimmune diseases, and most importantly type 2 Diabetes mellitus.  It does not require cutting into the stomach or bowel, nor leaving behind a foreign body.

    Please note Endoscopic Visceral Lipectomy has not yet been proven safe and effective and the EVL® device has not yet received regulatory approvals.

Management

Robert L. Cucin, MD FACS

CEO 

      Dr. Cucin is the Company's Founder and the inventor of its technology.  He received his undergraduate training at Cornell, his M.D. from Cornell Medical School and did both his General Surgery and Plastic & Reconstructive Surgery residences at The Presbyterian New York Hospital. He has a teaching appointment at the Weill Cornell Medical School. Dr. Cucin is a diplomate of the American Boards of Plastic Surgery, Surgery and Legal Medicine.  

     Dr. Cucin has a Columbia Business School M.B.A, a Juris Doctorate from Fordham Law School, and is duly admitted to the New York, New Jersey and D.C. Bars  Much of his research has been the subject of numerous contributions to the medical literature and he has published books in the fields of both medicine and law.

Deborah Salerno

CFO

     Ms. Salerno currently holds 7, 63 and 79 securities licenses. Managing Director of DAS Consulting LLC She been active in PIPE’s and provides expertise in  alternative financing.

    

Peter Ciriscioli, PhD

Consultant Engineer

    Dr. Ciriscioli was Program Manager of the Engineering Mechanics Laboratory at General Electric Corporate Research where he led new technology development and implementation throughout GE. Prior to that he worked as a consultant in technology strategy, technology transfer process, and product analysis for HEXCEL, a $1.5 Billion aerospace materials manufacturer.

   

    Dr. Ciriscioli received his B.S. and M.S. in Materials Science and Engineering from the University of California and a Ph.D in Mechanical Engineering from Stanford University. He has four patents, two books, and more than 20 published journal articles to his credit.

 The rest of the accomplished and talented management and advisory team adds a Harvard Law degree, a Yale M.D, an M.B.A. from Boston University, and even the rank of Brigadier General.

April 26, 2017


Robert L. Cucin MD, CEO, explains the science behind Endoscopic Visceral Lipectomy ("EVL") and the rationale for it as a treatment for Obesity and Type 2 Diabetes mellitus. 

Interviews and Presentations

July 3-16, 2017

 

CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature BioSculpture Technology, Inc. on The Documentary Channel beginning July 3-16, 2017, Monday – Friday between the hours of 6:00 am – 12:00 am. 

Note the Regulation A Offering alluded to in this video terminated on August 31, 2017.

June 16, 2016

 

Shelly Kraft of Stock News Now interviewed CEO Robert L. Cucin MD for an update at the Marcum MicroCap Conference in New York City

Note the Regulation A Offering alluded to in this video terminated on August 31, 2017.

August 1, 2017


Robert L. Cucin MD, CEO, narrates the highlights and gives an update of BioSculpture Technology, Inc.'s business plan. 

Note the Regulation A Offering alluded to in this video terminated on August 31, 2017.